Investigation of the vasorelaxant effects of 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1) and diethylamine/nitric oxide (DEA/NO) on the human radial artery used as coronary bypass graft

Can J Physiol Pharmacol. 2007 May;85(5):521-6. doi: 10.1139/y07-033.

Abstract

The radial artery (RA) is used as a spastic coronary bypass graft. This study was designed to investigate the mechanism of vasorelaxant effects of YC-1 (3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole), a nitric oxide (NO)-independent soluble guanylate cyclase (sGC) activator, and DEA/NO (diethylamine/nitric oxide), a NO-nucleophile adduct, on the human RA. RA segments (n = 25) were obtained from coronary artery bypass grafting patients and were divided into 3-4 mm vascular rings. Using the isolated tissue bath technique, the endothelium-independent vasodilatation function was tested in vitro by the addition of cumulative concentrations of YC-1 (10-10 to 3 x 10-7 mol/L) and DEA/NO (10-8 to 3 x 10-5 mol/L) following vasocontraction by phenylephrine in the presence or absence of 10-5 mol/L ODQ (1H-(1,2,4)oxadiazole(4,3-a)quinoxalin-1-one), the selective sGC inhibitor, 10-7 mol/L iberiotoxin, a blocker of Ca2+-activated K+ channels, or 10-5 mol/L ODQ plus 10-7 mol/L iberiotoxin. We also evaluated the effect of YC-1 and DEA/NO on the cGMP levels in vascular rings obtained from human radial artery (n = 6 for each drug). YC-1 (10-10 to 3 x 10-7 mol/L) and DEA/NO (10-8 to 3 x 10-5 mol/L) caused the concentration-dependent vasorelaxation in RA rings precontracted with phenylephrine (10-5 mol/L) (n = 20 for each drug). Pre-incubation of RA rings with ODQ, iberiotoxin, or ODQ plus iberiotoxin significantly inhibited the vasorelaxant effect of YC-1, but the inhibitor effect of ODQ plus iberiotoxin was significantly more than that of ODQ and iberiotoxin alone (p < 0.05). The vasorelaxant effect of DEA/NO almost completely abolished in the presence of ODQ and iberiotoxin plus ODQ, but did not significantly change in the presence of iberiotoxin alone (p > 0.05). The pEC50 value of DEA/NO was significantly lower than those for YC-1 (p < 0.01), with no change Emax values in RA rings. In addition, YC-1-stimulated RA rings showed more elevation in cGMP than that of DEA/NO (p < 0.05). These findings indicate that YC-1 is a more potent relaxant than DEA/NO in the human RA. The relaxant effects of YC-1 could be due to the stimulation of the sGC and Ca2+-sensitive K+channels, whereas the relaxant effects of DEA/NO could be completely due to the stimulation of the sGC. YC-1 and DEA/NO may be effective as vasodilator for the short-term treatment of perioperative spasm of coronary bypass grafts.

MeSH terms

  • Aged
  • Analysis of Variance
  • Coronary Artery Bypass / methods
  • Cyclic GMP / metabolism
  • Dose-Response Relationship, Drug
  • Enzyme Activators / pharmacology
  • Enzyme Inhibitors / pharmacology
  • Female
  • Humans
  • Hydrazines / pharmacology*
  • In Vitro Techniques
  • Indazoles / pharmacology*
  • Male
  • Middle Aged
  • Nitric Oxide Donors / pharmacology
  • Oxadiazoles / pharmacology
  • Peptides / pharmacology
  • Phenylephrine / pharmacology
  • Potassium Channels, Calcium-Activated / antagonists & inhibitors
  • Quinoxalines / pharmacology
  • Radial Artery / drug effects*
  • Radial Artery / metabolism
  • Radial Artery / physiology
  • Vasoconstrictor Agents / pharmacology
  • Vasodilation / drug effects*

Substances

  • 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one
  • Enzyme Activators
  • Enzyme Inhibitors
  • Hydrazines
  • Indazoles
  • Nitric Oxide Donors
  • Oxadiazoles
  • Peptides
  • Potassium Channels, Calcium-Activated
  • Quinoxalines
  • Vasoconstrictor Agents
  • 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole
  • Phenylephrine
  • iberiotoxin
  • 1,1-diethyl-2-hydroxy-2-nitrosohydrazine
  • Cyclic GMP